Why the study?
The study was conducted to evaluate D-dimer levels in patients with hypertrophic cardiomyopathy.
Elevated D-dimer is present in approximately 10% of patients with hypertrophic cardiomyopathy and is influenced by clinical factors such as age, sex, atrial fibrillation, and statin therapy.
Answers are grounded in this paper and cite their sources.
D-dimer elevation in HCM should not yet guide anticoagulation; leaves open its value for thrombosis risk stratification.
Aim: To evaluate D-dimer levels in patients with hypertrophic cardiomyopathy (HCM). Patients & methods: A total of 346 patients with HCM were recruited. Plasma D-dimer was determined by clinical laboratory of our hospital. Left ventricular mass, stroke volume, cardiac output and cardiac index were assessed with cardiovascular magnetic resonance. Results: A total of 36 (10.4%) patients had elevated D-dimer levels. Age, female patients and statin therapy were independently associated with increasing D-dimer levels, and predictors of elevated D-dimer. Conclusion: Patients with HCM may have higher plasma D-dimer levels than subjects without HCM. D-dimer levels in patients with HCM are influenced by age, sex, atrial fibrillation, statin therapy and diastolic blood pressure.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: